KROS241115P80000
- 0.00
- 0.000.00%
Keros Therapeutics Newsroom
Cantor Fitzgerald Initiates Keros Therapeutics(KROS.US) With Buy Rating
Keros Therapeutics Analyst Ratings
Keros Therapeutics Initiated With an Outperform at Scotiabank
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ironwood Pharma (IRWD), Travere Therapeutics (TVTX) and Keros Therapeutics (KROS)
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating
Truist Financial Reaffirms Their Buy Rating on Keros Therapeutics (KROS)
Guggenheim Initiates Keros Therapeutics(KROS.US) With Buy Rating, Announces Target Price $96
Keros Therapeutics Is Maintained at Buy by B of A Securities
Keros Therapeutics Analyst Ratings
BofA Securities Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $76
Analysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Harmony Biosciences Holdings (HRMY) and Keros Therapeutics (KROS)
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating
Oppenheimer Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $102
Oppenheimer Sticks to Its Buy Rating for Keros Therapeutics (KROS)
Strong Financials and Promising Clinical Trials Bolster Buy Rating for Keros Therapeutics
Buy Rating Affirmed for Keros Therapeutics as KER-065 Shows Promise in Obesity and Neuromuscular Disorders
TD Cowen Keeps Their Buy Rating on Keros Therapeutics (KROS)
Keros Therapeutics Analyst Ratings
Truist Securities Maintains Buy on Keros Therapeutics, Maintains $100 Price Target